GSK3862995B

Phase 2Small molecule

GSK

GSK3862995B is one of 101 small molecule programs targeting Bronchiectasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchiectasisRecruiting

Chronic Obstructive Pulmonary DiseaseRecruiting

Pulmonary Disease, Chronic ObstructiveRecruiting

ImmunogenicityNot yet recruiting

BronchiectasisPhase 2

Recruiting

Chronic Obstructive Pulmonary DiseasePhase 1

Recruiting

Pulmonary Disease, Chronic ObstructivePhase 1

Recruiting

ImmunogenicityPhase 1

Not yet recruiting

Competition

Competitive Landscape

119 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Lunsekimig

Sanofi

Phase 3

3 2

CM310

KKeymed Biosciences Co.Ltd

Phase 3

1 3

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 4

Astegolimab

Roche

Phase 3

2 5

Tozorakimab

AstraZeneca

Phase 3

2 6

GSK3862995B

GSK

Phase 2

1 7

Calciferol

Duragesic

2 9

Verekitug

UUpstream Bio Inc.

Phase 2

1 10

Narcan

SScienture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Chronic Obstructive Pulmonary Disease

NCT06154837

Q3 2027

Phase 1Recruiting

Pulmonary Disease, Chronic Obstructive

NCT07789899

Q4 2027

Phase 2Recruiting

Bronchiectasis

NCT07201051

Clinical

Trials by Indication[1]

Immunogenicity1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

Not yet recruiting· GSK logo

GSK·Phase 1·NCT06979518·30 enrolled

Chronic Obstructive Pulmonary Disease1 trial

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

Recruiting· GSK logo

GSK·Phase 1·NCT06154837·130 enrolled

Pulmonary Disease, Chronic Obstructive1 trial

A Phase 1, Open-Label, Randomized, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations After a Single Dose in Healthy Participants

Recruiting· GSK logo

GSK·Phase 1·NCT07789899·24 enrolled

Bronchiectasis1 trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis

Recruiting· GSK logo

GSK·Phase 2·NCT07201051·363 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for GSK3862995B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK3862995B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK3862995B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

GSK3862995B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Immunogenicity1 trial

Chronic Obstructive Pulmonary Disease1 trial

Pulmonary Disease, Chronic Obstructive1 trial

Bronchiectasis1 trial

References

Drug Info

Quick Facts

Related News